– USA, MA – Quanterix Corporation (NASDAQ: QTRX), a company digitizing biomarker analysis to advance the science of precision health, today announced the appointment of Karen Flynn to its Board of Directors effective June 6, 2022.
“We are pleased to welcome Karen to the Quanterix Board, bringing proven expertise that will be invaluable as a Director. As Quanterix continues executing on its next phase of growth, we are confident that Karen’s successful track record of developing and overseeing commercial and market strategies for global businesses will complement the skill sets already on our Board. We look forward to Karen’s guidance and perspective as the Company continues to expand the impact it has in powering advances in healthcare research and diagnostics,” said Executive Charmain, Kevin Hrusovsky.
About Karen A. Flynn
Karen Flynn is an accomplished healthcare leader with over 35 years of commercial, operations, and general management experience in the pharmaceutical services industry. She currently serves as CCO of Catalent Pharma Solutions, a global provider of development and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products. She previously served as the President of Catalent’s Biologics business. Before Catalent, she served as SVP and CCO for West Pharmaceutical Services and as President of West’s Pharmaceutical Packaging Systems business. In addition to her experience leading high-growth businesses, Ms. Flynn brings an extensive background in commercial strategy, strategic planning and innovation, and quality management. She previously served on the Board of Directors of Recro Pharma, Inc., specialty pharma and contract development and manufacturing organization focused on developing non-opioid products for acute pain and on solving complex formulation and manufacturing challenges primarily in small molecule therapeutic development.
“I am excited to join the Quanterix Board of Directors and work alongside a group of talented and distinguished board members during such an exciting time at the Company,” said Karen Flynn. “Quanterix is driving innovation that has the potential to deliver life-changing solutions in support of earlier disease detection, better prognoses, and enhanced treatment methods. With the Company’s strong foundation and focused vision for the future, Quanterix is well-positioned to further scale and strengthen its business and drive long-term value for shareholders. I look forward to supporting Quanterix’ continued success.”
Ms. Flynn received her Master of Science in Engineering from the University of Pennsylvania and Master of Science in Business Administration from Boston University. She received her Bachelor of Science in Pre-Professional Studies from the University of Notre Dame. Ms. Flynn has completed the Women’s Senior Leadership Program and the Corporate Governance, Effectiveness, and Accountability in the Board Room Program at Kellogg School of Management at Northwestern University and has been an active leader in the EcSell Institute Advisory Board, the Forum of Executive Women, the Healthcare Businesswomen’s Association and the Advisory Board for Downingtown STEM Academy. She has also received numerous awards, including the Silver Stevie Award for Women in Business and the Ellen Ann Roberts Business Award.
About Quanterix
Quanterix is a company that’s digitizing biomarker analysis to advance the science of precision health. The company’s digital health solution, Simoa, has the potential to change how healthcare is provided today by giving researchers the ability to closely examine the continuum from health to disease. Quanterix’ technology is designed to enable much earlier disease detection, better prognoses, and enhanced treatment methods to improve the quality of life and longevity of the population for generations to come. The technology is currently being used for research applications in several therapeutic areas, including oncology, neurology, cardiology, inflammation, and infectious disease. The company was established in 2007 and is located in Billerica, Massachusetts.
For more information: https://www.quanterix.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.